PHARMACEUTICAL COMPOSITION OF ENTEROSORBENT AND PREBIOTICS, MEDICAL FORMS AND METHOD OF PREVENTION AND TREATMENT OF DISEASES OF THE GASTROINTESTINAL TRACT

摘要

The pharmaceutical composition consists in the fact that it contains hydrolysis lignin with a moisture content of 55-65%, consisting of particles with a size of 0.15-0.55 mm, a 45-55% aqueous solution of lactulose and a 50-55% aqueous solution of oligosaccharides , in the following ratio of components, wt.%: aqueous solution of lactulose - 10-60; oligosaccharides - 10-50; hydrolytic lignin - the rest. The hydrolysis of lignin with lactulose and fructooligosaccharides is successively added and mixed using a rotary mixer. The composition is prescribed orally, for at least 14 and no more than 30 days, with a 2-4-fold daily intake, depending on the weight and age of the patient. The composition is used as a medicine for the treatment of diseases of the gastrointestinal tract, including intestinal infections of bacterial, viral and protozoal etiology; food poisoning and intoxication, acute and chronic hepatitis and cirrhosis, diarrhea, gastric and duodenal ulcer, Crohn's disease, ulcerative colitis, irritable bowel syndrome; disorders of mineral metabolism with a deficiency of Ca and Mg, including osteoporosis and other disorders of bone formation; as an immunomodulator in atopic dermatitis and immunodeficiency states; to protect and restore intestinal microflora after antibiotic therapy, chemotherapy and radiation therapy. The result consists in accelerating the achievement of results and increasing the effectiveness of the impact on the state of intestinal microbiocenosis, as well as the effectiveness of the treatment of hepatitis and cirrhosis, eliminating undesirable side effects when used in medical practice, and expanding the indications of medical use, i.e.